+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Deguelin

BP3110
522-17-8
98%
Phytounique
Derris trifoliata
Deguelin, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB. Deguelin is a potent in vitro inhibitor of the mutant form of NPM1, which provides the molecular basis for its anti-leukemia activities in NPM1 mutant acute myeloid leukemia cells.Deguelin has anti-cancer activity, such as anti osteosarcoma, lung cancer; via inducing the apoptosis of cancer cells through a ROS driven Akt pathway, EPC suppression by FAK-integrin-ILK-dependent actin remodeling .Deguelin possesses antitumor effect by targeting Akt in dual axis such as EGFR and IGF1R signaling pathways and suggests that it provides an applicable therapeutic strategy for HNSCC patients. Deguelin is a rotenone that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted by methoxy groups at positions 9 and 10, and by two methyl groups at position 3 (the 7aS,13aS-stereoisomer). It exists in abundant quantities in the bark, roots, and leaves of the Leguminosae family of plants and reported to exert anti-tumour effects in various cancers.
Catalog No Package Original Price Price Inventory Quantity Operating
BP3110-20mg 20mg
BP3110-100mg 100mg
BP3110-1000mg 1000mg
Chengdu Biopurify Phytochemicals Ltd.
Chengdu Biopurify Phytochemicals Ltd.

Related targets

GABAAR GLRA UNC49 AVR14 GLC1
BCL2 PIK3CA BCL2L1 AKT1 MTOR BCR-ABL STAT5 HSP90AA1
EGFR

Product drug property prediction parameters

  • 63.2200

  • 4.0244

  • 4.0244

  • .0037

  • 5.0804

  • 43.9069

  • High

  • 87.8522

  • 3.6984

  • No

  • No

  • Yes

  • No

  • Yes

  • Yes

  • 0.6

  • No

  • Yes

  • No

  • Yes